Building on current butyrate modification strategies, we also review its applications in drug formulation enhancement and synergistic therapeutic combinations
An assessment of the expression of key OXPHOS subunit proteins (succinate dehydrogenase B [SDHB], Ubiquinol-Cytochrome C Reductase Core Protein 2 [UQCRC2], Mitochondrially Encoded Cytochrome C Oxidase I [MTCO1], ATP synthase subunit alpha of complex V [vATP5A]), revealed no change in the protein content with NR co-treatment, suggesting the improved mitochondrial respiration rates observed are likely related to mitochondrial functional capacity improvements rather than mitochondrial content improvements (Fig 2HL)
Initially, the research focused on treating diabetes and cardiovascular diseases (9,10,17,18)
and Eli Lilly, which sells its medications under the Mounjaro and Zepbound trade names
Istvn Pcsi, University of Debrecen, Hungary Updates Copyright 2019 Traynor, Sheridan, Jones, Calera and Doyle
The enhanced efficacy profile potentially reduces treatment duration and improves patient compliance, translating to better therapeutic value propositions
